In the Media

Prof. Robert Langer, cofounder of Moderna, speaks to The Boston Globe’s Marin Wolf and Jonathan Saltzman about the company’s successful results of a personalized messenger RNA vaccine in a late-stage trial to treat melanoma. “So far, the only proof is with melanoma, but it’s a stunning example of what can be done,” says Langer. “I don’t see any reason why it wouldn’t work with other types of cancer.”